Regulatory Approval

Health Canada's approval of a generic Wegovy promises to slash costs and expand access, shifting the landscape for patients and the healthcare system.

With FDA clearance, Gain Therapeutics' GT-02287, an AI-discovered drug, advances to Phase 2, offering a new hope to modify Parkinson's, not just its symptoms.

With FDA approval for its pivotal TRIUMPH trial, Laplace Interventional is challenging giants in the lucrative tricuspid valve market. A strategic play.

Manitoba Hydro's plan for a major natural gas expansion sparks a fierce debate over energy needs, climate goals, and the future of the province's grid.

Onkos Surgical hit 500 cases with its NanoCept antibacterial coating. Is this nano-scale tech the key to winning the war on devastating surgical infections?

GuideAI Health's new AI platform just hit the public market. It promises to find hidden vascular disease in routine scans, but can it navigate the risks?

Binance's landmark offering of SpaceX shares in ADGM isn't just about access; it's a blueprint for the future of regulated digital asset markets.

With a new FDA Fast Track designation, Satellos Bioscience aims to accelerate its unique muscle-regenerating drug for Duchenne, a strategy that could sidestep genetic limitations.

With FDA clearance and strategic provincial funding, Conavi Medical's dual-imaging system isn't just a new device; it's a new playbook for medtech.

Bullish secures key approval in Gibraltar for tokenized securities, a strategic move paired with its Equiniti acquisition to build a regulated, end-to-end digital asset ecosystem.

Merck's new HIV drug, IDVYNSO™, gets a crucial boost via a public health deal, signaling a strategic play to reclaim ground in a multi-billion dollar market.

Larimar Therapeutics is rewriting the rare disease playbook. Its BLA filing for nomlabofusp leverages a novel FDA-aligned endpoint, creating a de-risked path to market.

Viridian's Lumvoa gains FDA approval for Thyroid Eye Disease, challenging a blockbuster drug and validating DRI Healthcare's unique royalty investment model.

For over a million Europeans with Parkinson's, a new drug promises longer periods of symptom control. But the path from regulatory approval to patient is complex.

A newly approved Swedish mine could break Europe's reliance on China for critical minerals, but it sits on the edge of a vital lake, pitting strategic need against local fears.

Ottawa approves a key road to the Ring of Fire, balancing Indigenous-led growth against deep environmental and inter-community rifts. What does this signal?

Nemaska Lithium plans a major expansion of its Whabouchi mine, testing Canada's regulations and pitting the global hunger for EV minerals against local concerns.

A new DARPA-backed technology from ARA uses biological principles to create life-saving medicines on-demand, bypassing fragile supply chains for the military.

A new program gives Georgia's largest companies direct control over their green energy sourcing. Is this a model for the future or a subsidy in disguise?